EUVIMEDEUVIMED entdecken
Crossref

High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma – A Single Center Case Series

Paul Schwarzlmueller iD, Stefanie Corradini iD, Max Seidensticker iD, Petra Zimmermann, Jochen Schreiner, Tanja Maier, Alexandra Triebig, Thomas Knösel iD, Montserrat Pazos, Thomas Pfluger, Isabel Weigand iD, Claus Belka und 4 weitere

Hormone and Metabolic Research · 01.01.2024 · 56 (01) · 30-37

DOI: 10.1055/a-2150-3944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.01.2024. Verfasst von Paul Schwarzlmueller und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Brachytherapy, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The response rate of advanced adrenocortical carcinoma (ACC) to standard chemotherapy with mitotane and etoposide/doxorubicin/cisplatin (EDP-M) is unsatisfactory, and benefit is frequently short lived. Immune checkpoint inhibitors (CPI) have been examined in patient’s refractory to EDP-M, but objective response rates are only approximately 15%. High-dose rate brachytherapy (HDR-BT) is a catheter-based internal radiotherapy and expected to favorably combine with immunotherapies. Here we describe three cases of patients with advanced ACC who were treated with HDR-BT and the CPI pembrolizumab. None of the tumors were positive for established response markers to CPI. All patients were female, had progressed on EDP-M and received external beam radiation therapy for metastatic ACC. Pembrolizumab was initiated 7 or 23 months after brachytherapy in two cases and prior to brachytherapy in one case. Best response of lesions treated with brachytherapy was complete (n=2) or partial response (n=1) that was ongoing at last follow up after 23, 45 and 4 months, respectively. Considering all sites of tumor, response was complete and partial remission in the two patients with brachytherapy prior to pembrolizumab. The third patient developed progressive disease with severe Cushing’s syndrome and died due to COVID-19. Immune-related adverse events of colitis (grade 3), gastroduodenitis (grade 3), pneumonitis (grade 2) and thyroiditis (grade 1) occurred in the two patients with systemic response. HDR-BT controlled metastases locally. Sequential combination with CPI therapy may enhance an abscopal antitumoral effect in non-irradiated metastases in ACC. Systematic studies are required to confirm this preliminary experience and to understand underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenocortical CarcinomaBrachytherapyAdrenal Cortex NeoplasmsHumansFemaleMaleProgrammed Cell Death 1 ReceptorAntineoplastic Combined Chemotherapy Protocols

Substanzen

Programmed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.
  • Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
  • Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Department of General, Visceral and Transplant Surgery, University Hospital, LMU Munich, Munich, Germany.
  • Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
  • Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.

ORCID-Profile: Paul Schwarzlmueller, Stefanie Corradini, Max Seidensticker, Thomas Knösel, Isabel Weigand, Martin Reincke, Matthias Kroiss

Zitieren

APA

Schwarzlmueller, P., Corradini, S., Seidensticker, M., Zimmermann, P., Schreiner, J., Maier, T., Triebig, A., Knösel, T., Pazos, M., Pfluger, T., Weigand, I., Belka, C., Ricke, J., Reincke, M., Schmidmaier, R., & Kroiss, M. (2024). High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma – A Single Center Case Series. Hormone and Metabolic Research, 56(01), 30-37. https://doi.org/10.1055/a-2150-3944

Vancouver

Schwarzlmueller P, Corradini S, Seidensticker M, Zimmermann P, Schreiner J, Maier T, et al. High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma – A Single Center Case Series. Hormone and Metabolic Research. 2024;56(01):30-37. doi:10.1055/a-2150-3944

BibTeX
@article{Schwarzlmueller2024,
  author = {Schwarzlmueller, Paul and Corradini, Stefanie and Seidensticker, Max and Zimmermann, Petra and Schreiner, Jochen and Maier, Tanja and Triebig, Alexandra and Knösel, Thomas and Pazos, Montserrat and Pfluger, Thomas and Weigand, Isabel and Belka, Claus and Ricke, Jens and Reincke, Martin and Schmidmaier, Ralf and Kroiss, Matthias},
  title = {High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma – A Single Center Case Series},
  journal = {Hormone and Metabolic Research},
  year = {2024},
  volume = {56},
  number = {01},
  pages = {30--37},
  doi = {10.1055/a-2150-3944}
}
Kostenlos starten →